Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | FOS | P01100 | 1/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5729627 | 1.00 | CYP2A6 (0.50) | CYP2A6LMNAPPARGMEN1KMT2A | |
| SCHEMBL13012173 | 0.94 | LMNA (0.45) | CYP2A6LMNAPPARGMEN1KMT2A | |
| SCHEMBL8790770 | 0.82 | LMNA (0.51) | CYP2A6LMNAPPARGMEN1KMT2A | |
| SCHEMBL950722 | 0.80 | HSD17B10 (0.52) | PPARGNFE2L2PTGES2FBP1ALOX5 | |
| SCHEMBL950718 | 0.80 | HSD17B10 (0.52) | PPARGNFE2L2PTGES2FBP1ALOX5 | |
| SCHEMBL11336851 | 0.79 | MAOB (0.50) | PTGS2MAOB | |
| SCHEMBL11336850 | 0.79 | MAOB (0.50) | PTGS2MAOB | |
| SCHEMBL1122349 | 0.78 | KMT2A (0.47) | MEN1KMT2ANFE2L2FBP1ALOX5 | |
| SCHEMBL8414375 | 0.78 | APP (0.41) | LMNAPPARGNFE2L2PTGS1CA1 | |
| SCHEMBL947253 | 0.78 | PTGES2 (0.44) | PPARGPTGES2CA1TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216954-B2 | Serine racemase inhibitor | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2015-12-22 | — | — | US | disclosed |
| US-9216954-B2 | Serine racemase inhibitor | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2015-12-22 | — | — | US | disclosed |
| US-9145380-B2 | Bis-(sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2015-09-29 | — | — | US | disclosed |
| US-20140371291-A1 | SERINE RACEMASE INHIBITOR | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371291-A1 | SERINE RACEMASE INHIBITOR | NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-2808014-A1 | SERINE RACEMASE INHIBITOR | National University Corporation University Of Toyama (JP) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013111798-A1 | SERINE RACEMASE INHIBITOR | 国立大学法人 富山大学 (JP) | 2013-08-01 | — | — | WO | disclosed |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| EP-1188755-B1 | ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6723722-B1 | BLOOD COAGULATION FACTOR X INHIBITORS; ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-20 | — | — | US | disclosed |
| EP-1188755-A1 | ACYLHYDRAZINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371291-A1 | SERINE RACEMASE INHIBITOR | SRR, PRSS1, ME1 | CYP2A6 2914/4885LMNA 3748/4885PPARG 4614/4885 |
| US-20100331321-A1 | Bis-(Sulfonylamino) derivatives for use in therapy | PTGER1, SULT2A1, SULT1E1 | CYP2A6 39/4885LMNA 1049/4885PPARG 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.